[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538744":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":30,"responsibleParty":42,"collaborators":30,"id":46,"slug":30,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":30,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":72,"whyStopped":30,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":30},{"fullName":5,"class":6},"University of Arizona","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"4-aminopyridine","ACTIVE_COMPARATOR","Study drug: dalfampridine (generic) 10mg ER capsule",[13],"Drug: 4-Aminopyridine",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo-1 capsule",[19],"Other: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","4-Aminopyridine","Subjects will receive either the active study drug (4-aminopyridine) or placebo to determine the effects of 4AP on carpal tunnel syndrome",[9],[27],"4AP",{"type":6,"name":15,"description":24,"armGroupLabels":29,"otherNames":30},[15],null,[32],{"name":33,"affiliation":5,"role":34},"John Elfar, MD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},"Carly Deal","CONTACT","520-626-4656","carlyjdeal@arizona.edu",{"name":33,"role":38,"phone":30,"phoneExt":30,"email":30},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"SPONSOR_INVESTIGATOR","John Elfar","Tenured Professor, Chairman, Department of Orthopaedic Surgery","100538744",false,"NCT06294821","4AP for Carpal Tunnel Syndrome (CTS)","4-Aminopyridine to Delay Carpal Tunnel Release or Resolve Carpal Tunnel Syndrome","CTS","Inclusion Criteria:\n\n* Patients diagnosed with non-traumatic carpal tunnel syndrome without any other confounding diagnosis (e.g. cubital tunnel syndrome, cervical nerve compression)\n* Standard of care EDX testing within 6 months of study enrollment\n* Cognitive ability to report sensory and motor deficit during examination.\n* Able to complete twice daily dosing of 4-AP for the entire 6 week treatment period.\n* Adults subject aged 18-90\n* Ability to give written informed consent.\n* Capable of safely undergoing electrodiagnostic testing (EDX).\n* Availability for all study visits.\n\nExclusion Criteria:\n\n* Inability to complete twice daily dosing during 6 week treatment period.\n* History of multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of hypersensitivity to AMPYRA® or 4-aminopyridine\n* Current use of aminopyridine medications, including other compounded 4-AP\n* Suspected renal impairment based on the Choyke questionnaire.","ALL","18 Years","90 Years",{"count":57,"type":58},160,"ESTIMATED","INTERVENTIONAL",[61],"PHASE2","The investigators have found recent promising data supporting the use of a currently FDA approved drug, 4-aminopyridine, in the treatment of nerve injury including compression neuropathy. The purpose of this research is determine whether 4-aminopyridine can treat carpal tunnel syndrome or delay the need for formal surgical release in patients with known carpal tunnel syndrome who would otherwise undergo surgery.",[64,65],"Compression Neuropathy","Carpal Tunnel Syndrome",[67,68,69,27,51,70,71],"4 aminopyridine","carpal tunnel syndrome","CTR","Carpal tunnel release","compression neuropathy","NOT_YET_RECRUITING","2026-01-22",{"date":75,"type":76},"2026-01-26","ACTUAL",{"date":78,"type":58},"2026-11",{"date":80,"type":58},"2028-07",{"name":44,"class":6}]